Why Did BofA Securities Give Globus Medical A Double Upgrade?

Enabling tech is likely to continue driving Globus Medical Inc’s GMED market share gains in 2022, according to BofA Securities.

The Globus Medical Analyst: Craig Bijou upgraded the rating for Globus Medical from Underperform to Buy, while raising the price target from $55 to $80.

The Globus Medical Thesis: The pullback in the stock over the past month, following reports of the acquisition of NuVasive, Inc. NUVA and on COVID-19 omicron variant concerns, “provides a particularly attractive entry point,” Bijou said in the upgrade note.

The NuVasive acquisition is unlikely, the analyst mentioned. He added, “as we wrote at the time. COVID remains a risk to volume, but believe GMED should outperform peers during any flare-ups as it has over the last two years.”

“We see upside potential to the 10% consensus top-line growth next year as the growing robot installed base, increased utilization and new enabling tech products should further drive implant pull through and disposable/service revenue,” Bijou further wrote.

GMED Price Action: Shares of Globus Medical had risen by 2.37% to $69.56 at the time of publication Monday morning.

Photo by National Cancer Institute on Unsplash

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorNewsUpgradesHealth CarePrice TargetAnalyst RatingsGeneralBofA SecuritiesCraig Bijoumedical devices
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!